Evaluation of the parameters affecting the loading of anticancer drug Paclitaxel on coated gold nanoparticles for breast cancer treatment.


Journal

IET nanobiotechnology
ISSN: 1751-875X
Titre abrégé: IET Nanobiotechnol
Pays: United States
ID NLM: 101303205

Informations de publication

Date de publication:
May 2023
Historique:
revised: 28 01 2023
received: 03 10 2022
accepted: 07 02 2023
medline: 19 5 2023
pubmed: 1 3 2023
entrez: 28 2 2023
Statut: ppublish

Résumé

The purpose of this study is the design and synthesis of gold nanoparticles (GNPs) conjugated with paclitaxel and to investigate the parameters affecting the stability of synthesised nanoparticles with drug delivery capability. Here, synthesised GNPs were coated with polyethylene glycol. Then these particles were conjugated with paclitaxel under different conditions and the physical and structural characteristics, as well as the factors affecting the loading of paclitaxel on nanoparticles, were evaluated by ultraviolet spectrophotometer, fourier transform infrared spectroscopy, transmission electron microscopy, dynamic light scattering and zeta potential apparatus. It was found that pegylated GNPs have a limited loading capacity at the time of 24 h of incubation and the Paclitaxel loading was observed to be pH dependent. The use of these particles in the treatment of breast cancer (MCF7) was also investigated using the MTT test. It was determined that the survival percentage of MCF7 cells in the presence of paclitaxel-bound nanoparticles decreases to about 55% at the maximum measured concentration (690 μM).

Identifiants

pubmed: 36849875
doi: 10.1049/nbt2.12121
pmc: PMC10190534
doi:

Substances chimiques

Paclitaxel P88XT4IS4D
Gold 7440-57-5
Antineoplastic Agents 0
Polyethylene Glycols 3WJQ0SDW1A

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

234-245

Informations de copyright

© 2023 The Authors. IET Nanobiotechnology published by John Wiley & Sons Ltd on behalf of The Institution of Engineering and Technology.

Références

J Nanobiotechnology. 2015 Mar 26;13:26
pubmed: 25880772
IET Nanobiotechnol. 2023 May;17(3):234-245
pubmed: 36849875
Bioconjug Chem. 2016 Nov 16;27(11):2646-2657
pubmed: 27689882
Cancers (Basel). 2015 Dec 03;7(4):2360-71
pubmed: 26633515
Acta Histochem. 2006;108(5):327-34
pubmed: 16730054
J Occup Med Toxicol. 2007 Dec 01;2:16
pubmed: 18053152
Oncol Rep. 1996 Jan;3(1):147-50
pubmed: 21594333
Mol Med Rep. 2020 Dec;22(6):4475-4484
pubmed: 33173972
Phys Med Biol. 2010 Jun 7;55(11):3045-59
pubmed: 20463371
Adv Drug Deliv Rev. 2017 Dec 1;122:20-30
pubmed: 28257998
IET Nanobiotechnol. 2020 Jul;14(5):396-404
pubmed: 32691742
Spectrochim Acta A Mol Biomol Spectrosc. 2005 Oct;61(13-14):2861-6
pubmed: 16165025
J Control Release. 2009 Jan 5;133(1):11-7
pubmed: 18950666
Molecules. 2020 Mar 05;25(5):
pubmed: 32151062
Curr Pharm Biotechnol. 2020;21(4):305-315
pubmed: 31729941
J Med Chem. 2006 Dec 14;49(25):7253-69
pubmed: 17149855
Acc Chem Res. 2008 Dec;41(12):1721-30
pubmed: 18712884
Nature. 1996 Aug 15;382(6592):607-9
pubmed: 8757129
Pharm Dev Technol. 2020 Apr;25(4):397-407
pubmed: 31893979
Int J Mol Sci. 2011;12(7):4395-413
pubmed: 21845085
N Engl J Med. 2007 Dec 27;357(26):2666-76
pubmed: 18160686
Inflammopharmacology. 2008 Jun;16(3):112-25
pubmed: 18523733
Int J Nanomedicine. 2016 Feb 26;11:791-822
pubmed: 27013874
Int J Pharm. 2007 Sep 5;342(1-2):208-14
pubmed: 17560058
Langmuir. 2005 Dec 6;21(25):11562-7
pubmed: 16316080
Drug Deliv Transl Res. 2013 Dec;3(6):499-503
pubmed: 24932437
Chem Rev. 2004 Jan;104(1):293-346
pubmed: 14719978
Toxicol Sci. 2004 Jan;77(1):117-25
pubmed: 14514968
Polymers (Basel). 2020 Feb 02;12(2):
pubmed: 32024289
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S847-S854
pubmed: 30449179
Acc Chem Res. 2008 Dec;41(12):1842-51
pubmed: 19053240
J Thorac Dis. 2017 Mar;9(3):448-451
pubmed: 28449441
Cancer Biol Ther. 2008 Jun;7(6):911-6
pubmed: 18367873
Expert Opin Drug Deliv. 2010 Jun;7(6):753-63
pubmed: 20408736
Drugs. 1994 Nov;48(5):794-847
pubmed: 7530632
Cancer Lett. 1997 May 1;115(1):25-30
pubmed: 9097975
Anticancer Agents Med Chem. 2021;21(17):2429-2442
pubmed: 33342419

Auteurs

Afrooz Kharazmi (A)

Department of Biomedical Engineering, Applied Biophotonics Research Center, Tehran Science and Research Branch, Islamic Azad University, Tehran, Iran.

Neda Attaran (N)

Department of Medical Nanotechnology, Applied Biophotonics Research Center, Tehran Science and Research Branch, Islamic Azad University, Tehran, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH